# Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients

Study · id `cardio:ct-nct05761444` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05761444](<https://clinicaltrials.gov/study/NCT05761444>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05761444

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 137 participants.

## Technical summary

Registry record NCT05761444. Randomized; no masking; primary purpose treatment. Start 2023-07-26 (actual); primary completion 2024-09-04 (actual). Results posted on 2025-09-09.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 137 participants (enrolled count; ClinicalTrials.gov record NCT05761444, source copy `cardio:ctgov-nct05761444-2025-09-09`, retrieved 2026-10-31)
- Started: 2023-07-26 (actual) (ClinicalTrials.gov record NCT05761444, source copy `cardio:ctgov-nct05761444-2025-09-09`, retrieved 2026-10-31)
- Primary completion: 2024-09-04 (actual) (ClinicalTrials.gov record NCT05761444, source copy `cardio:ctgov-nct05761444-2025-09-09`, retrieved 2026-10-31)
- Completion: 2024-10-15 (actual) (ClinicalTrials.gov record NCT05761444, source copy `cardio:ctgov-nct05761444-2025-09-09`, retrieved 2026-10-31)
- Results first posted: 2025-09-09 (ClinicalTrials.gov record NCT05761444, source copy `cardio:ctgov-nct05761444-2025-09-09`, retrieved 2026-10-31)
- Countries: South Korea (ClinicalTrials.gov record NCT05761444, source copy `cardio:ctgov-nct05761444-2025-09-09`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05761444-2025-09-09`, retrieved 2026-10-31)

## The registry's words

- Brief title: Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients
- Acronym: BETTER
- Condition: Atherosclerotic Cardiovascular Disease
- Intervention (Drug): Atozet 10/40 mg or 10/80 mg
- Intervention (Drug): Lipitor 40 mg or 80 mg
- Lead sponsor: Organon and Co
- Lead sponsor class: INDUSTRY
- Collaborator: IQVIA Pty Ltd
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry lists this organization as the lead sponsor: Organon and Co (`cardio:org-organon-and-co`)
- Registry lists this organization as a collaborator: IQVIA Pty Ltd (`cardio:org-iqvia-pty-ltd`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: The role of early ezetimibe combination with atorvastatin in patients with atherosclerotic cardiovascular disease (`cardio:pubmed-41673582`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 17d846d9453e4c7c556d56d1a521508091b9d1352a9e098db22052947a50305c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
